Live feed08:00:00·1dPRReleasevia QuantisnowTakeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)ByQuantisnow·Wall Street's wire, on your screen.TAK· Takeda Pharmaceutical Company LimitedHealth Care
